BeiGene shares new Tevimbra data at ESMO 2024

BeiGene announced it will share new data for Tevimbra at the European Society of Medical Oncology 2024 Congress, or ESMO 2024, in Barcelona, Spain, September 13-17. BeiGene has seven abstracts accepted at ESMO 2024, with one selected for the special session revisiting the ESMO Virtual Plenary held in February. As an encore to the ESMO plenary, interim results from the RATIONALE-315 study show the statistically significant event-free survival, or EFS, and trend for overall survival, or OS, benefit favoring neoadjuvant tislelizumab plus chemotherapy with adjuvant tislelizumab vs. placebo plus chemotherapy with adjuvant placebo for patients with resectable non-small cell lung cancer, or NSCLC. These results further reinforce the data presented at ESMO 2023 showing major pathologic response, or MPR, and pathologic complete response, or pCR, rate were significantly improved: 56.2% vs 15.0% and 40.7% vs 5.7%, respectively. The safety profile of the tislelizumab arm was consistent with that of individual therapies, with 72.1% of patients in the tislelizumab arm experiencing grade 3 treatment-related adverse events, or TRAEs, and 15.5% experiencing serious TRAEs. The most common TRAEs were decreased neutrophil count, decreased white blood cell count and alopecia. Improvement in symptomology from RATIONALE-315 will also be shown as patient-reported outcomes. Three-year overall survival data from RATIONALE-305 continue to demonstrate the long-term efficacy and safety of tislelizumab plus chemotherapy in patients with first-line advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC) (poster #1437P, Sept. 16), as well as improvements in patient-reported outcomes (poster #1449P, Sept. 16). Long-term outcomes in the ITT population as well as those receiving long-term exposure to tislelizumab plus chemotherapy as treatment for first line squamous NSCLC in RATIONALE-307 show a continued OS benefit with clinically promising four-year OS rates (poster #1323P, Sept. 14). Relative effectiveness of tislelizumab vs. other anti-PD-1 treatments approved in the European Union and UK for second-line esophageal squamous cell carcinoma (ESCC) using anchored simulated treatment comparison of data from RATIONALE-302 and comparator clinical studies (poster #1417P, Sept. 16).